Managers / Q1 2026
NVP Associates, LLC
CIK 0001545692 · 1300 EL CAMINO REAL, SUITE 200, MENLO PARK, CA, 94025 · 650-321-8000
Summary
Nvp Associates, LLC reported $176M in U.S.-listed holdings across 5 positions for Q1 2026.
The portfolio is heavily concentrated: MBX alone accounts for 36.2% of reported value.
Compared with Q4 2025, the fund opened 0 new positions and exited 1.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 100.0% · $176M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2025 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| TALKTALKSPACE INC | SOLD OUT | −9.80M | 0 | −$36M | $0 |
| ZBIOZENAS BIOPHARMA INC | HELD | +0 | 1.84M | −$31M | $36M |
| OMDAOMADA HEALTH INC | HELD | +0 | 2.53M | −$8M | $32M |
| MBXMBX BIOSCIENCES INC | HELD | +0 | 2.14M | −$4M | $64M |
| BLLNBILLIONTOONE INC | HELD | +0 | 513.3K | −$1M | $41M |
| GROVGROVE COLLABORATIVE HOLD INC | HELD | +0 | 3.23M | +$580,517 | $4M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2026
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | MBXMBX BIOSCIENCES INChistory → | COM | 36.20% | $64M | 2.14M |
| 2 | BLLNBILLIONTOONE INChistory → | CL A | 23.00% | $41M | 513.3K |
| 3 | ZBIOZENAS BIOPHARMA INChistory → | COM | 20.40% | $36M | 1.84M |
| 4 | OMDAOMADA HEALTH INChistory → | COM | 18.06% | $32M | 2.53M |
| 5 | GROVGROVE COLLABORATIVE HOLD INChistory → | COM CL A | 2.34% | $4M | 3.23M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $176M | 5 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $255M | 6 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $166M | 5 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $184M | 7 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $112M | 6 | May 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $187M | 7 | Feb 10, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $176M | 8 | Nov 12, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $91M | 6 | Aug 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $126M | 6 | May 10, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $112M | 6 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $112M | 8 | Nov 8, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $115M | 9 | Aug 1, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $87M | 8 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $102M | 8 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.